📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-08-29 17:04
0 analysed today
FollowTelegram
0
Today
151,853
All-time analysed
43,533
Positive
6,742
Negative
92,741
Neutral
8,769
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
2 announcements match the current filters (relevance ≥ 5).
Promoter Swapan Khandelwal acquires 0.81% stake (78,000 shares) via open market
Goldline Pharmaceutical Ltd has received a disclosure under SEBI SAST Regulation 29(2) regarding insider share purchases. Promoter and Whole Time Director Mr. Swapan Khandelwal acquired 78,000 equity shares through the open market on August 28, 2026. This transaction represents approximately 0.81% of the company's total issued and paid-up share capital.
Confidence: HIGH
What changedPromoter and Whole Time Director Swapan Khandelwal increased his stake in the company by purchasing 78,000 shares (0.81%) on August 28, 2026.
Why it mattersOpen-market purchases by key promoters and executive directors typically signal management confidence in the company's operational prospects and underlying valuation.
Shares acquired: 78000Stake acquired: 0.81%Acquisition date: 28.08.2026
📅 Short termMay provide positive sentiment support to the stock as insider buying from key management indicates internal confidence.
📈 Long termSignals aligned promoter interests, though operational execution and earnings growth remain the primary drivers.
Key Highlights
Promoter & Whole Time Director Swapan Khandelwal acquired 78,000 equity shares
Acquisition represents 0.81% of total paid-up share capital
Transaction conducted via open market on August 28, 2026
Disclosure filed pursuant to Regulation 29(2) of SEBI SAST Regulations, 2011
👀 What to Watch
Track further shareholding disclosures to see if promoter buying continues across upcoming quarters.
Goldline Pharma seeks approval for ₹200 Cr director loan limit with equity conversion option
Goldline Pharmaceutical has issued a notice for its 22nd AGM on August 29, 2026, proposing significant financial resolutions. The company seeks shareholder approval to borrow up to ₹200 Cr from directors, with a provision to convert these unsecured loans into equity shares. This limit is highly material, representing approximately 6.4x the company's FY26 revenue of ₹31.2 Cr. Additionally, the company is seeking a ₹200 Cr limit for loans and guarantees to entities where directors are interested, alongside ratifying material related party transactions.
Confidence: HIGH
What changedThe company is seeking to significantly expand its financial headroom by authorizing a borrowing and lending limit that is disproportionately large compared to its current scale of operations.
Why it mattersThe ₹200 Cr limit suggests a massive potential capital infusion or expansion plan; however, the ability to convert director debt to equity at a later stage could lead to substantial dilution for minority shareholders.
Proposed Borrowing Limit: ₹200 CrLimit vs FY26 Revenue: 641%Limit vs Net Worth: 1428%FY26 Revenue: ₹31.2 CrFY26 Net Profit: ₹4.12 Cr
📅 Short termThe stock may see volatility as investors assess the implications of the large borrowing limit and the potential for future equity dilution.
📈 Long termWhile the capital could fund major growth, the high volume of related party transactions and the scale of the borrowing limit relative to current equity require long-term monitoring of corporate governance.
⚠ Risk flags
- Significant potential equity dilution from loan conversion
- High volume of material related party transactions
- Borrowing limit is extremely high relative to current revenue and net worth
Key Highlights
Proposed borrowing limit of ₹200 Cr from directors, which is ~14x the current net worth of ₹14 Cr
Provision for converting director loans into fully paid-up equity shares at SEBI-regulated prices
Approval sought for loans, investments, or guarantees up to ₹200 Cr under Section 185 for subsidiaries/associates
Ratification of material related party transactions with Activista Healthcare, Nucleage Pharma, and Numerius Healthcare
FY26 annual revenue stood at ₹31.2 Cr with a net profit of ₹4.12 Cr
👀 What to Watch
Investors should closely monitor the AGM voting results and seek clarity on the specific end-use of the proposed ₹200 Cr borrowing, as well as the potential dilution impact from the debt-to-equity conversion clause.
